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(http://creativecommontify amyloid-b (Ab) pathology in Alzheimer’s disease (AD) patients. Here, we determined the diag-
nostic value of the amyloid PET tracer [18F]flutemetamol in relation to Ab pathology at autopsy.
Methods: [18F]flutemetamol PETwas carried out in a cohort of 68 patients included in a [18F]flute-
metamol amyloid PET imaging end-of-life study (GE067-007). At autopsy, AD pathology was deter-
mined and Ab plaque pathology was classified into phases of its regional distribution (0–5).
Results: [18F]flutemetamol PET was universally positive in cases with advanced stage postmortem
Ab pathology (Ab phases 4 and 5). Negative amyloid PETwas universally observed in nondemented
or non-AD dementia cases with initial Ab phases 1 and 2, whereas 33.3% of the phase 3 cases were
positive.
Conclusions: [18F]flutemetamol amyloid PET detects primarily advanced stages of Ab pathology in
preclinical and symptomatic AD cases.
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s.org/licenses/by-nc-nd/4.0/).detection of amyloid pathology in the human brain has
become feasible by the use of [11C]- and [18F]-labeled
amyloid binding ligands and positron emission
tomography (PET) [3–6]. In vitro-labeling experiments
with the [11C]-labeled amyloid tracer Pittsburg
compound B (PIB) disclose plaques on histopathologic
slides [7]. Autopsies performed on AD subjects that
received amyloid PET before death have shown that areas
with a high plaque density showed ligand retention with
amyloid PET [8–10].
Neuropathologically, the deposition of Ab plaques starts
in the neocortex and then expands hierarchically into further
brain regions [11]. In the second phase, allocortical plaqueser’s Association. This is an open access article under the CCBY-NC-ND license
D.R. Thal et al. / Alzheimer’s & Dementia 11 (2015) 975-985976occur, whereas in phase 3, additional plaques are found in
the basal ganglia and in the diencephalon, in phase 4 in
the midbrain and the medulla oblongata, and in the fifth
and final phase also in the cerebellum and the pons. These
phases of Ab deposition are associated with the parallel
development of neurofibrillary tangle (NFT) pathology in
the course of preclinical and symptomatic AD. Ab phases
4 and 5 are almost always associated with symptomatic
AD [11]. The current guidelines of the National Institute
of Aging and the Alzheimer Association (NIA-AA) for the
neuropathologic diagnosis of AD recommend the assess-
ment of the Ab phases in concert with the Braak stages for
NFT pathology (Braak-NFT stage) and the Consortium to
establish a Registry for AD (CERAD) score for the assess-
ment of the frequency of neuritic plaques [12]. According
to these guidelines, Ab deposition in the brain indicates
the presence of AD pathology regardless of cognitive deficits
[12]. Because clinical AD by definition is restricted to
demented individuals [13], the diagnosis of preclinical AD
(pre-AD) has been introduced for nondemented cases with
positive AD biomarkers [14]. Histopathologically, detect-
able AD pathology in nondemented cases may, therefore,
be classified as pathologically defined pre-AD (p-pre-AD)
cases [15,16].
Until now, it was not clear whether amyloid PET up-
take mirrors the hierarchical pattern of Ab plaque deposi-
tion, and if so, which phases of Ab pathology might be
detectable with amyloid PET imaging techniques, or
how accurate amyloid PET might be for the differential
diagnosis between autopsy proven AD, p-pre-AD, non-
AD dementias, such as vascular dementia, Lewy body dis-
ease (LBD) or frontotemporal lobar degeneration (FTLD),
and nondemented non-AD cases. [18F]flutemetamol is
structurally similar to PIB [17] and has recently been vali-
dated for the detection of amyloid plaques [10]. We
compared [18F]flutemetamol amyloid PET with the amy-
loid plaque phase, neuritic plaque density, and associated
NFT pathology in 68 autopsy cases enrolled in the [18F]
flutemetamol amyloid PET imaging end-of-life study
(GE067-007).2. Material and methods
2.1. Subjects
The subject cohort of 68 cases was included in the effi-
cacy analysis of theGE-067-007 Phase 3 end-of-life clinical
trial and autopsied after death (Table 1). Dementia, defined
according to the Diagnostic and Statistical Manual of
Mental Disorders, Fourth Edition (DSM-IV) criteria, was
noted as present or absent. This was a phase 3, multicenter
PET study of [18F]flutemetamol injection for detecting
brain Ab (ClinicalTrials.gov identifier NCT01165554).
Local institutional review boards or ethics committees
approved the study protocol before initiation. All subjects
or their legal representatives gave prior written informedconsent/assent. Consecutive eligible subjects were
55 years of age, terminally ill with a life expectancy
,1 year, and with general health adequate to undergo study
procedures. Patients died of natural causes and serious
adverse events were not attributable to [18F]flutemetamol
injection [10]. Subjects were ineligible if they were preg-
nant/lactating, had known/suspected structural brain abnor-
malities, contraindication(s) for PET, known/suspected
hypersensitivity/allergy to [18F]flutemetamol injection (or
any component), or had participated in any clinical study us-
ing an investigational product within 30 days of signing con-
sent. The scan-death intervals ranged between 0 and
397 days (mean 104 days; median 78 days).2.2. Neuropathology assessments
Brain material received at autopsy and previously used for
diagnostic purposes supporting the GE067-007 phase 3 clin-
ical trial was examined. All brains were formalin fixed. The
brainswere cut in coronal slices and screenedmacroscopically
for the presence of infarcts, hemorrhages, tumors, and inflam-
matory lesions. For histopathologic analysis and for assessing
the amounts of AD-related amyloid plaques, NFTs, and
neuritic plaques, we examined paraffin-embedded tissue
including parts of the frontal, parietal, temporal, occipital cor-
tex, and entorhinal cortex, the hippocampal formation at the
level of the lateral geniculate body, basal ganglia, thalamus,
amygdala, midbrain, pons, medulla oblongata, and cere-
bellum. Paraffin sections of 5 mm thickness from all blocks
were stained with hematoxylin & eosin (H&E) and anti-Ab
antibodies (1:100, formic acid and heat pretreatment; anti-
Ab; 4G8, SIG-39220; Covance, USA). For neuropathologic
diagnosis, sections were stained with the Bielschowsky silver
method and immunohistochemical methods for abnormal
phosphorylated tau protein (anti-human PHF-tau monoclonal
antibody; AT8, prod. no. MN1020, 1:40; Thermo Scientific,
UK), a-synuclein (anti-a-synuclein monoclonal antibody;
prod. no. NCL-L-ASYN, lot no. 6005209, 1:40; Leica Micro-
systems, UK), and ubiquitin (anti-ubiquitin polyclonal anti-
body; prod no. Z0458, 1:400; DakoCytomation, UK).
Primary antibodies were detected with biotinylated secondary
antibodies (E0354, DakoCytomation) and visualized with the
DABMapKit (Ventana,USA).Thephase ofAbplaquepathol-
ogy (Ab phase) was assessed after screening the Ab-stained
sections for plaque distribution according to previously pub-
lished protocols [11,18]. The neuropathologic diagnosis of
AD pathology was performed as recommended (Table 2)
[12]. Ab plaques loads were determined in 32 cases as shown
in Supplmentary Fig. 3.
Additional vascular changes were assessed in H&E-
stained sections. LBD and multiple system atrophy–related
changes were determined using a-synuclein immunohisto-
chemistry. Other tauopathies (FTLD-tau) were diagnosed
on the basis of antiabnormal tau protein–stained sections.
Ubiquitin-stained sections were used to identify other types
of FTLD or motor neuron disease.
Table 1
List of cases
Case
number
Age,
y Sex
Neuropathologic
diagnosis Dementia
Clinicopathologic
AD
classification
Amyloid
PET
classification Ab phase
Braak
stage
CERAD
sore
for neuritic
plaques
NIA-AA
degree
of AD
Scan-death
interval SUVRCER SUVRPONS
1 80 M AD 1 AD Positive 5 6 3 3 0 1.996 0.665
2 72 M AD 1 AD Positive 5 6 3 3 1 2.37 0.786
3 85 M AD 1 AD Positive 5 5 2 3 394 2.825 0.881
4 83 M AD 1 AD Positive 5 6 3 3 33 2.595 0.8
5 85 F AD 1 AD Positive 5 6 3 3 127 2.902 0.89
6 80 M AD 1 AD Positive 5 6 3 3 170 2.335 0.757
7* 88 F AD, DLB 1 AD 1 non-AD dementia Positive 5 6 2 3 78 1.674 0.663
8 76 F AD, CAA 1 AD Positive 5 6 3 3 26 1.832 0.683
9 65 F AD 1 AD Positive 5 6 3 3 139 2.366 0.822
10 74 M AD, CAA 1 AD Positive 5 4 2 2 372 1.476 0.54
11 78 M AD, DLB 1 AD 1 non-AD dementia Positive 5 6 2 3 61 2.859 0.872
12 80 M AD, DLB 1 AD 1 non-AD dementia Positive 5 6 1 2 2 2.101 0.793
13 78 F AD, DLB 1 AD 1 Non-AD Dementia Positive 5 6 3 3 124 2.122 0.697
14 73 F AD 1 AD Positive 5 6 3 3 26 2.228 0.7
15 84 M AD, CAA, multiple
infarcts
1 AD 1 non-AD dementia Positive 5 6 2 3 59 2.81 0.958
16 94 F AD 1 AD Positive 5 3 1 2 19 1.953 0.741
17 87 M AD 1 AD Positive 5 6 3 3 105 2.201 0.728
18 95 F AD 1 AD Positive 5 6 2 3 14 1.887 0.863
19 83 F AD 1 AD Positive 5 5 2 3 193 2.399 0.79
20 87 F DLB, AD 1 AD 1 non-AD dementia Positive 5 4 1 2 130 1.95 0.736
21 86 F AD 1 AD Positive 5 5 3 3 154 2.426 0.946
22 75 F AD 1 AD Positive 5 6 3 3 65 2.465 0.886
23 88 F AD, DLB, CAA,
arteriolosclerosis
1 AD 1 non-AD dementia Positive 5 6 2 3 114 2.385 0.874
24 81 F AD, DLB 1 AD 1 non-AD dementia Positive 4 4 2 2 126 2.323 0.99
25 80 M AD 1 AD Positive 4 6 2 3 276 2.334 0.861
26 87 M AD 1 AD Positive 4 4 2 2 22 2.041 0.623
27 89 M AD pathology, DLB 1 Non-AD dementia Positive 4 2 2 1 307 2.186 0.708
28 82 M AD, CAA 1 AD Positive 4 6 3 3 14 2.234 0.741
29 77 F AD pathology, LBD 1 Non-AD dementia Positive 4 1 3 1 179 2.03 0.688
30 87 F AD pathology, DLB,
arteriolosclerosis,
infarct
1 Non-AD dementia Positive 4 2 1 1 118 3.137 0.862
31 83 F AD 1 AD Positive 4 6 3 3 198 1.483 0.594
32 90 F AD 1 AD Positive 4 6 3 3 50 2.349 0.868
33 77 F AD 1 AD Positive 4 6 3 3 10 1.59 0.879
34 91 F AD, CAA 1 AD Positive 4 6 3 3 55 2.2 0.748
35 91 M AD 1 AD Positive 4 5 2 3 29 1.857 0.614
36 81 M AD, DLB, CAA 1 AD 1 non-AD dementia Positive 4 6 3 3 204 2.414 0.815
37 91 F AD, DLB 1 AD 1 non-AD dementia Positive 4 3 1 2 131 2.719 0.785
38 87 M AD, CAA 1 AD Positive 4 4 3 2 1 2.098 0.822
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Table 1
List of cases (Continued )
Case
number
Age,
y Sex
Neuropathologic
diagnosis Dementia
Clinicopathologic
AD
classification
Amyloid
PET
classification Ab phase
Braak
stage
CERAD
sore
for neuritic
plaques
NIA-AA
degree
of AD
Scan-death
interval SUVRCER SUVRPONS
39 85 F AD, DLB 1 AD 1 non-AD dementia Positive 4 3 2 2 192 2.067 0.655
40 79 M AD pathology, CAA,
metastatic carcinoma
2 p-pre-AD Positive 4 3 2 2 41 2.441 0.898
41* 91 F AD pathology, CAA,
LBD
1 Non-AD dementia Negative 4 2 1 1 209 1.549 0.598
42 60 M AD pathology, CAA (focal) 1 Non-AD dementia Negative 4 2 1 1 10 1.083 0.372
43 76 M DLB 1 Non-AD dementia Positive 3 2 2 1 83 1.874 0.737
44 81 F DLB, AD 1 AD 1 non-AD dementia Positive 3 4 2 2 183 1.661 0.646
45 84 M Vascular dementia 1 Non-AD dementia Positive 3 2 2 1 44 1.851 0.591
46 92 M DLB 2 p-pre-AD Negative 3 2 2 1 322 1.355 0.482
47 72 F DLB 2 p-pre-AD Negative 3 1 2 1 294 1.76 0.589
48 71 M PiD 1 Non-AD dementia Negative 3 0 1 1 142 1.014 0.339
49 86 M AD 1 AD Negative 3 3 2 2 18 1.451 0.503
50 87 F Vascular dementia 1 Non-AD dementia Negative 3 1 1 1 76 1.569 0.493
51 75 M DLB, infarcts 1 Non-AD dementia Negative 3 2 2 1 63 1.227 0.44
52 74 M Multiple infarct dementia 1 Non-AD dementia Negative 2 0 0 1 169 1.119 0.365
53 84 F Vascular dementia 1 Non-AD dementia Negative 2 2 1 1 68 1.363 0.502
54 86 F Aging changes,
arteriolosclerosis
1 Non-AD dementia Negative 2 0 1 1 136 1.527 0.47
55 89 F CAA, NFT-predominant
dementia, AD pathology
1 Non-AD dementia Negative 2 4 1 1 77 1.252 0.408
56 75 F Normal 1 Non-AD dementia Negative 2 1 0 1 9 1.558 0.536
57 89 F Infarct, arterolosclerosis 1 Non-AD dementia Negative 1 3 1 1 114 1.404 0.379
58* 72 F NFT-predominant
dementia
1 Non-AD dementia Negative 1 5 0 1 104 1.343 0.409
59* 82 F DLB 1 Non-AD dementia Negative 1 3 1 1 24 1.723 0.458
60 76 F DLB, vascular dementia 1 Non-AD dementia Negative 1 2 0 1 145 1.218 0.408
61 60 F Normal 2 p-pre-AD Negative 1 0 0 1 34 1.669 0.589
62 84 M Normal 1 Non-AD dementia Negative 0 1 0 0 16 1.18 0.371
63 91 M Vascular dementia,
early stage PSP
1 Non-AD dementia Negative 0 0 0 0 130 1.344 0.4
64 66 M Aging changes 1 Non-AD dementia Negative 0 0 0 0 154 1.298 0.453
65 70 M Normal 2 Non-AD Negative 0 0 0 0 15 1.44 0.489
66 63 M Normal 2 Non-AD Negative 0 0 0 0 12 1.597 0.473
67 67 M Normal 2 Non-AD Negative 0 1 0 0 32 1.369 0.466
68* 79 M AGD 1 Non-AD dementia Negative 0 3 0 0 130 1.259 0.445
Abbreviations: M, male; F, female; AD, Alzheimer’s disease; PET, positron emission tomography; Ab, amyloid-b; NIA-AA, National Institute of Aging and the Alzheimer Association; SUVRCER, cerebellum
standard uptake value ratio; SUVRPONS, pons cerebellum standard uptake value ratio; DLB, Dementia with Lewy Bodies; CAA, cerebral amyloid angiopathy; LBD, Lewy Body Disease (includes DLB); PiD,
Pick’s Disease (FTLD-tau subtype); NFT, neurofibrillary tangle; PSP, pregressive supranuclear palsy (FTLD-tau subtype); AGD, Argyrophilic Grain Disease (FTLD-tau subtype).
NOTE. Cases with a positive [18F]flutemetamol amyloid PETwere given in boldface. Case numbers marked with “*” indicate cases who received 185 MBq. All other cases received an injection of 370 MBq
[18F]flutemetamol. Dementia: “1” indicates demented; “2” indicates not demented. Ab-phase, Braak-NFT Stage, CERAD Neuritic Plaque Score, and NIA-AA degree of AD Pathology were determined as
previously published [11,12,35,36]. Scan-death interval in days.
D
.R
.
T
h
a
l
et
a
l.
/
A
lzh
eim
er’s
&
D
em
en
tia
1
1
(2
0
1
5
)
9
7
5
-9
8
5
9
7
8
Table 2
Pathologic and clinicopathologic classification criteria as applied in this study
A: Amyloid score
(amyloid plaque phase)
C: CERAD (neuritic
plaque score)
B: NFT score (Braak-NFT stage)
B0 or B1 (I/II) B2 (III/IV) B3 (V/VI)
A0 (0) C0 (0) No AD No AD No AD
A1 (1/2) C0/1 (0/1) Low Low Low
C2/3 (2/3) Low Intermediate Intermediate
A2 (3) Any C Low Intermediate Intermediate
A3 (4/5) C0/1 (0/1) Low Intermediate Intermediate
C2/3 (2/3) Low Intermediate High
No AD/no PART PART
NFT-predominant
dementia p-pre-AD
Symptomatic
AD
Symptomatic AD 1
non-AD dementia
Non-AD
dementia
B score 0 B1–B2 B2–B3 B0–B3 B2–B3 B2–B3 B0–B2
Degree of AD pathology No AD No AD No AD or low Low–high Intermediate–high Intermediate–high No AD or low
Clinical signs of dementia or
cognitive decline
No No Yes No Yes Yes Yes
Dementing disorder other
than AD
No No Yes (NFT-predominant
dementia)
No No Yes Yes
Abbreviations: NFT, neurofibrillary tangle; AD, Alzheimer’s disease; PART, primary age-related tauopathy; p-pre-AD, pathologically defined pre-AD.
NOTE. A: Determination matrix for the NIA-AA Degree of AD pathology regardless of the clinical status as previously published [12]. Ab phase, Braak-NFT stage and CERAD score for neuritic plaques are
required to determine the NIA-AA degree of AD pathology [11,35,36].
B: Subclassification of p-preAD, symptomatic AD, symptomatic ADwith non-AD dementia (i.e. mixed dementia), non-AD dementia, definite PARTand definite NTF-predominant dementia with respect of the
clinical status [13,14,16,19,37,38].
There may be overlap between p-pre-AD and PART if one does not restrict to definite PARTwithout any Ab pathology as done here. NFT-predominant dementia has been included in PART but an alternative
classification for FTLD terms demented cases with this type of pathology NFT-predominant dementia [19,37]. To avoid confusion, we used the term NFT-predominant dementia for the demented “PART” cases.
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Demented cases with at least intermediate NIA-AA de-
grees of AD pathology [12] were considered as symptomatic
AD cases; nondemented individuals with AD pathology
were referred to as p-pre-AD cases as previously suggested
[15,16] (Table 2). Nondemented cases without AD pathol-
ogy were classified as non-AD controls. Non-AD controls
included cases with NFT pathology in the medial temporal
lobe that recently has been termed primary age-related tau-
opathy [19] (Table 2). Patients with non-AD dementia en-
compassed demented patients with vascular dementia,
LBD, and FTLD-tau (argyrophilic grain disease, NFT-
predominant dementia, Pick’s disease) that did not exhibit
intermediate or high degrees of AD pathology indicating
that AD pathology was presumably not responsible for de-
mentia. Cases with intermediate or high degrees of AD pa-
thology and apparent lesions of a second dementia-related
disorder were classified as a subgroup of AD cases:
AD 1 non-AD dementia (identical with mixed dementia;
Table 2).Fig. 1. Boxplot diagram of Ab phase, Braak-NFT stage, CERAD score for
neuritic plaque pathology and the NIA-AA degree of AD pathology for
cases with negative (n 5 25) and positive amyloid PET pattern (n 5 43).
*P , .05 in a logistic regression model controlled for age, sex, scan-death
interval, and Braak-NFT stage. Abbreviations: NFT, neurofibrillary tangle;
NIA-AA, National Institute of Aging and the Alzheimer Association; AD,
Alzheimer’s disease; PET, positron emission tomography; Ab, amyloid-b;
CT, computed tomography.2.4. [18F]flutemetamol PET image assessments
Amyloid PET imaging was performed at 12 different im-
aging sites (Supplementary Methods). Before PET imaging,
subjects underwent head computed tomography (CT) or
magnetic resonance imaging, unless prior images (obtained
within 12 months) were available. [18F]flutemetamol injec-
tion was administered intravenously at a dose of 185 or
370 MBq of radioactivity at physician discretion
(Supplementary Methods). PET images were acquired in
2-minute frames on PET/CT cameras, beginning approxi-
mately 90 minutes after injection. Five frames were summed
to give a 10-minute scan, which was attenuation corrected
using CT data. Equipment used to capture images varied
across the 12 imaging sites (Supplementary Methods).
Most images were reconstructed iteratively to form 128 !
128 axial slices, and a Gaussian post-reconstruction smooth-
ing filter was applied to some. The images were evaluated
over all as either positive or negative for amyloid by five in-
dependent readers blinded to all clinical, demographic, and
pathology information. The readers were experienced nu-
clear medicine physicians or radiologists scoring PET im-
ages with knowledge of the respective CT scans. The
results reported here are using the majority read for global
classification of the GE067-007 images from a reread study
(GE-067-021) after automated reader training
(Supplementary Fig. 1, Supplementary Methods).
The [18F]flutemetamol standard uptake values (SUVs)
were measured for five volumes of interest (VOIs) restricted
to gray matter and adjusted for atrophy manually, covering
the anterior cingulate, the prefrontal cortex, the lateral tem-
poral cortex, the parietal cortex, and one VOI covering both
posterior cingulate and precuneus (Supplementary Fig. 2).
Frame-to-frame motion correction was performed on the dy-namic data before quantitative SUVmeasurements and stan-
dard uptake value ratio (SUVR) calculations were made. As
reference for cerebellum SUV (SUVRCER), the cerebellar
gray matter SUV was used. To exclude bias by using the
cerebellar gray matter as reference, we also obtained SUV
for the pons as a reference. SUVRs were calculated as a ratio
of cortical region SUV to either the SUVRCER reference or
pons SUV reference (SUVRPONS). A global cortical average
(composite SUVR) was calculated averaging the cortical
SUVRs. Image processing and VOI analysis were performed
using voyager 4 (GE Healthcare, Uppsala, Sweden).2.5. Statistical analysis
Logistic regression analysis, analysis of variance (AN-
OVA) and Fisher’s exact test were calculated using SPSS
21 statistical software (IBM, Armonk, NY, USA)
(Supplementary Methods).3. Results
3.1. [18F]flutemetamol amyloid PET: Association with
Ab-phases
Most (89%) Ab phase 4 and all Ab phase 5 cases ex-
hibited a positive amyloid PET signal, whereas all Ab phase
0, 1, and 2 cases showed a negative PET. Only 33.3% of the
Ab phase 3 cases exhibited a positive amyloid PET (Fig. 1,
Table 1). This finding was confirmed by measuring Ab pla-
que loads in 32 of our cases providing a threshold of an Ab
plaque load of 5% for [18F]flutemetamol amyloid PET
Fig. 2. Composite neocortical SUVRCER levels of [
18F]flutemetamol reten-
tion do not increase significantly until and including Ab phase 3 but are
significantly increased in cases of Ab phases 4 and 5. Circles represent out-
liers. **P,.01. (Ab phase 0: n57;Abphase 1: n55;Ab phase 2: n55;Ab
phase 3: n5 9; Ab phase 4: n5 19; andAb phase 5: n5 23). Abbreviations:
SUVRCER, cerebellum standard uptake volume ratio; Ab, amyloid-b.
D.R. Thal et al. / Alzheimer’s & Dementia 11 (2015) 975-985 981positivity (Supplementary Fig. 3). Likewise, high Braak-
NFT stages and high CERAD neuritic plaques scores as
well as high and intermediate NIA-AA degrees of AD pa-
thology were observed in cases with positive PET uptake,
whereas cases with a negative amyloid PET exhibited either
no or only low degrees of NFT, neuritic plaque pathology as
well as low NIA-AA degrees AD pathology or no AD pa-
thology (Fig. 1, Table 1).
Two cases with NFT-predominant dementia with Braak-
NFT stages IV and V showed a negative amyloid PET.
Higher densities of neuritic plaques (moderate or frequent)
were commonly found in AD cases with a positive amyloid
PET although 13 cases with a sparse to moderate neuritic
plaque density had negative amyloid PET scans (Table 1).
In a logistic regression model controlled for age, sex, and
scan-death interval Ab phases had a significant influence on
the amyloid PET pattern, whereas NFT stages did not show a
significant effect on the amyloid PET pattern (Ab phases:
P 5 .006, odds ratio [OR]: 12.98, 95% confidence interval
[CI]: 2.065–81.583; Braak-NFT stages: P 5 .092). The CE-
RAD score for neuritic plaque density was not integrated in
this model because of collinearity with the Ab plaque phase.
A significant association between the amyloid PET pattern,
on the one hand, the Braak-NFT stage and the CERAD
neuritic plaque density score, on the other, was observed
in separate models without Ab-phase (Braak-NFT stages:
P , .001, OR: 3.275, 95% CI: 1.886–5.687; CERAD score:
P , .001, OR: 21.023, 95% CI: 4.026–109.772). These re-
sults were expected from previously published data exam-
ining the associations between NFT pathology and neuritic
and Ab plaque pathology [15,20].
In agreement with the dichotomous [18F]flutemetamol
PET assessment as negative or positive, cortical composite
SUVRCER did not show differences among individual Ab
phase 0–2 subjects (Fig. 2; SUVRCER,1.6 except two phase
1 cases: 1.67, 1.72). Phase 3 subjects rated as positive had
SUVRCER levels between 1.66 and 1.87. Cases with negative
PET assessment had SUVRCER levels ,1.6 except for one
case with a SUVRCER of 1.76 (Fig. 2). Cases with Ab phases
4 and 5 identified as having a positive amyloid [18F]fluteme-
tamol retention pattern had increased cortical SUVRCER
(.1.6). Only two phase 4 (1.48 and 1.59) and one phase 5
case had lower SUVRCER levels (1.48). The two Ab phase
4 cases with a negative [18F]flutemetamol PET exhibited
SUVRCER levels ,1.6. Overall, cases with Ab phases 4
and 5 had significantly higher SUVRs than those in lower
phases (ANOVA P  .006, corrected for multiple testing
with Games-Howell post hoc test). Similar differences
have been found when using SUVRPONS instead of
SUVRCER for statistical analysis (Supplementary Table 1).3.2. [18F]flutemetamol amyloid PET differentiates AD
cases from non-AD dementia, p-pre-AD, and no AD cases
Positive amyloid PET scans were obtained in all cases
with AD-type mixed dementia, i.e. cases with intermediateto high AD pathology according to the NIA-AA criteria
and significant signs of a second dementing disorder
(Fig. 3A, Tables 1 and 2) and in 96.2% of the pure AD
cases. Only one demented case with intermediate AD
pathology did not exhibit a positive PET signal. This case
exhibited Ab phase 3 (Table 1).
One of four nondemented p-pre-AD cases (25%)
exhibited a positive amyloid PET (Fig. 3A, Table 1). In
non-AD dementia cases with no or low degrees of AD
pathology amyloid PET images were positive in 21.7%
(Fig. 3A, Table 1) and such cases exhibited Ab phase 3 or
4 (Fig. 3A, Table 1).
Binary logistic regression analysis in a model
controlled for age, sex, and scan-death interval revealed
that positive [18F]flutemetamol amyloid PET uptake pat-
terns identified symptomatic AD cases including those
with additional non-AD pathology rather than nonde-
mented p-pre-AD and non-AD controls (P 5 .008; OR:
143.05; 95% CI: 4.681–4371.714). Likewise, symptom-
atic AD (including those cases with additional non-AD
pathology) was distinguished from pure non-AD demen-
tias (P , .002; OR: 155.199; 95% CI: 15.541–
1549.928). Differences in the SUVRCER levels confirmed
the distinction of AD cases (including cases with fully
developed AD pathology and additional non-AD pathol-
ogy) from non-AD, and non-AD dementia cases
(Fig. 3B; ANOVA P  .001, corrected for multiple testing
with Games-Howell post hoc test). Subjects with
p-pre-AD (n 5 4) were not distinguished from nonde-
mented control subjects (n 5 3) by [18F]flutemetamol
amyloid PET pattern (P 5 1.0, Fisher’s exact test) or by
SUVRCER differences (Fig. 3; P 5 .655, ANOVA cor-
rected for multiple testing with Games-Howell post hoc
test) in our sample. Similar results have been obtained
Fig. 3. (A) Boxplot diagram showing the distributions of negative and pos-
itive [18F]flutemetamol amyloid PET pattern in non-AD, p-pre-AD, symp-
tomatic AD with and without copathology of other dementing disorders,
and in non-AD dementia cases (i.e., FTLD, vascular dementia, and LBD).
AD cases with and without copathology exhibited positive [18F]flutemeta-
mol amyloid PET pattern, whereas non-AD, p-pre-AD, and non-AD demen-
tia cases did not. (B) Composite [18F]flutemetamol SUVRCER levels
confirmed the increase in [18F]flutemetamol retention in AD cases with or
without additional dementia-related pathologies in comparison to non-AD
and non-AD dementia cases. *5 outlier. ***P , .0001. (non-AD controls:
n5 3; p-pre-AD: n5 4; AD: n5 26; AD1 non-AD dementia: n5 12; and
non-AD dementia: n 5 23). Abbreviations: PET, positron emission tomog-
raphy; AD, Alzheimer’s disease; p-pre-AD, pathologically defined pre-AD;
FTLD, frontotemporal lobar degeneration; LBD, Lewy body disease;
SUVRCER, cerebellum standard uptake volume ratio; CT, computed tomog-
raphy.
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analysis (Supplementary Table 1).4. Discussion
The key novel finding in this study is that [18F]flutemeta-
mol amyloid PET detects Ab pathology only in cases with
advanced phases of plaque pathology at autopsy, that is, pri-
marily Ab phases 4 and 5 (Fig. 4). This finding was
confirmed by measuring Ab plaque loads as shown in
Supplementary Fig. 3. An additional major finding is that
[18F]flutemetamol amyloid PET primarily detects Ab plaque
pathology in AD cases with advanced stage Ab pathologyrepresenting Ab phases 4 and 5 permitting the distinction be-
tween AD and non-AD dementias. In contrast, p-pre-AD
cases with Ab phases 1–2 did not exhibit a positive [18F]flu-
temetamol PET pattern and did not differ in cortex
SUVRCER levels from non-AD control cases (Fig. 3 and 4).
Only three of nine Ab phase 3 cases exhibited a positive im-
aging pattern, and each of these cases was demented. Only one
nondemented case with a positive [18F]flutemetamol amyloid
PETwas observed. However, this case had significant AD pa-
thology with Ab phase 4 and Braak-NFT stage III. As such,
given the current rating protocols [18F]flutemetamol amyloid
PET analysis allowed a clear cut distinction of .95% of the
symptomatic AD subjects with or without additional neurode-
generative pathology from cases free of AD pathology, p-pre-
AD cases and cases with non-AD dementias, that is, FTLD,
LBD, and vascular dementia. Amyloid PET did not allow a
distinction between pure AD cases and AD cases with addi-
tional LBD or additional vascular pathology, most likely
because both groups exhibited Ab phases 4 or 5. It is well
known that amyloid tracers detect plaque pathology in a sub-
group of aged nondemented individuals [21–24]. Our finding
that only those nondemented cases with Ab pathology
representing advanced phases (i.e., phase 3 and higher) were
identified by [18F]flutemetamol amyloid PET points to the
interpretation that amyloid PET detects only a subgroup of
the p-pre-AD cases: those cases that are close to the
threshold of symptomatic AD. Ab plaque load measurements
confirmed this interpretation. This finding is in line with the
report of amyloid PET-negative cases already showing AD-
related cerebrospinal fluid Ab changes [25].
Furthermore, amyloid PET with florbetapir (another
amyloid tracer) was reported to be positive in cases
considered neuropathologically as definite or probable
AD, whereas cases categorized as no AD or possible
AD with Ab plaque loads up to 1.14% did not exhibit a
positive florbetapir PET [9]. Because densitometric mea-
surements of immunoreactivity in general depend on the
staining and cutting protocols as well as on correction fil-
ters and threshold settings [26] and vary among different
laboratories [27], Ab plaque loads determined here and
by Clark et al. [9] cannot be compared directly with
one another. Thus, threshold differences of approximately
3%–4% between both studies do not necessarily contradict
the comparability of both tracers with PIB as previously
published [28]. In this study we, therefore, chose the
phases of Ab plaque distribution [11] as a parameter for
Ab plaque pathology. This has proven to generate highly
reliable and valid information on the amount of Ab plaque
pathology as demonstrated in interlaboratory and interrater
studies by BrainNet Europe [18,29]. The increased
likelihood of future cognitive decline in amyloid PET-
positive nondemented individuals [21–24] is in
agreement with the detection of advanced stage Ab
pathology in the nondemented individuals as seen in our
autopsy study.
Fig. 4. Schematic representation of Ab plaque pathology in different Ab phases with corresponding [18F]flutemetamol amyloid PET images. Cases with early
Ab phases 1–3 did not exhibit a significant [18F]flutemetamol retention, whereas symptomatic or preclinical AD cases with Ab phases 4 and 5 showed positive
[18F]flutemetamol retention. Parts of this figure are reproduced with permission from Thal DR, et al. Phases of Abeta-deposition in the human brain and its
relevance for the development of AD. Neurology 2002;58:1791–800. [11]. Abbreviations: Ab, amyloid-b; PET, positron emission tomography; AD, Alz-
heimer’s disease; p-pre-AD, pathologically defined pre-AD.
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yloid plaques in Tg2576 mice and in AD patients [30–32].
The fact that cortical Ab plaques and neuritic plaques in
Ab phase 1 and 2 cases as well as in 66.7% of the Ab
phase 3 cases were not detected by [18F]flutemetamol
PET demonstrates that amyloid PET is not sensitive
enough to detect initial stages of these pathologies. Only
increased numbers of cortical plaques usually associated
with increased amounts of cortical soluble and
nonplaque-associated insoluble (so called dispersible)
Ab aggregates in Ab phase 4 and 5 cases [15,16]
permitted significant [18F]flutemetamol retention in the
cortex. The assumption of a threshold for Ab pathology
to be passed for detection with amyloid PET is in
agreement with the negative PIB amyloid imaging
results in aged monkeys with amyloid plaques that may
not exhibit sufficient degrees of amyloid pathology (as
Ab phase 1–3 cases in this study) to allow detection by
amyloid PET methods [33].
Based on composite SUVRCER of cortical regions [
18F]
flutemetamol amyloid PETwas not sensitive enough for the
detection of the hierarchical pattern of Ab plaque expan-
sion in the human brain seen neuropathologically [11].
This finding is in line with that of other authors [34] and
highlights the fact that amyloid PET is not as precise asthe gold standard of neuropathologic analysis and should
be interpreted carefully as only bulk effects will be identi-
fied, whereas minor effects may be difficult to detect. More-
over, our finding of no significant increase of cortical
composite SUVRCER between Ab phases 0–3 points to
interindividual SUVR differences that should not be misin-
terpreted as early Ab deposition in studies without patho-
logic confirmation. More detailed studies of pathology
and amyloid PET in nondiseased individuals will be
required to identify algorithms to distinguish no AD from
p-pre-AD cases.
The use of the cerebellum or the pons as reference re-
gions for SUVR calculation and the inclusion of only
cortical regions into composite SUVRs preclude the detec-
tion of amyloid deposits in these regions characteristic for
end-stage AD [11] and explain the failure of current amy-
loid PET rating strategies in the detections of a hierarchical
pattern of Ab deposition. For this purpose, SUVR levels of
the brain stem, basal ganglia, and the thalamus would be
required as well.
The selection of cerebellum or pons as reference regions,
however, appears to be reasonable for amyloid PET given
the fact that these two regions are the last to develop Ab pla-
ques in end-stage AD, whereas all other brain regions are
affected earlier. Composite SUVRCER and SUVRPONS,
D.R. Thal et al. / Alzheimer’s & Dementia 11 (2015) 975-985984thereby, showed similar effects related to the Ab phases
(Supplementary Table 1).
The neuritic plaque density as determined by the CERAD
semiquantitative score confirmed the association of the am-
yloid PET pattern with the plaque load as described in detail
by Curtis et al. [10]. All amyloid PET-positive cases had at
least sparse neuritic plaques. [18F]flutemetamol PET did
not detect severe abnormal tau pathology in cases with
NFT-predominant dementia in line with previously pub-
lished data for PIB [8].
One limitation in this study is the variable delay be-
tween the last PET scan and death, ranging between
0 and 397 days (mean 104 days; median 78 days), during
which AD pathology could have progressed. To minimize
the potential error induced by variable scan-death inter-
vals, we included this parameter in the logistic regression
model, although our cohort had shorter average scan-
death interval compared to a similar study which had a
scan-death interval up to 2 years [9].
Our finding that a distinct subgroup of p-pre-AD cases
with very early phases of Ab deposition was not detected
by [18F]flutemetamol amyloid PET indicates that p-pre-
AD cases can be subdivided into amyloid PET-positive
clinically detectable cases and amyloid PET-negative pre-
sumably clinically “normal” p-pre-AD cases. The fact that
[18F]flutemetamol PET tracer retention was restricted to
cases with already advanced stages of Ab pathology (Ab
phase 3 and higher) may have an impact on the interpretation
and design of clinical studies in amyloid PET-positive non-
demented individuals because at this stage the amyloid load
is already high.
In summary, by identifying amyloid phase 4 and 5 cases,
[18F]flutemetamol PET is well suited to detect amyloid pa-
thology in symptomatic AD and mixed dementia cases
with a significant AD component. Nondemented cases
with a positive amyloid PET included in this study had
advanced Ab pathology at autopsy and, therefore, represent
pathologically and clinically diagnosed pre-AD cases. Am-
yloid PET-negative p-pre-AD cases were related to the
very early phases of Ab pathology. However, such amyloid
PET-negative p-pre-AD cases do already show initial AD pa-
thology at autopsy.Acknowledgments
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1. Systemic review: The authors reviewed literature
related to amyloid positron emission tomography
(PET) in Alzheimer’s disease (AD) and its relation
to neuropathologic lesions using PubMed andGoogle
Scholar. Relevant work has been cited.
2. Interpretation: Our findings indicate that amyloid
PET is an excellent tool for the differential diagnosis
between AD and non-AD dementia cases. Moreover,
we provide evidence that amyloid PET currently
identifies pathologically diagnosed preclinical AD
(p-pre-AD) cases at an already advanced point in the
evolution of the disease.
3. Future directions: The use of amyloid PET to identify
patients with preclinical phases of AD for therapeutic
trials selects already biologically advanced phases of
p-pre-AD. It is, therefore, essential to generate algo-
rithms for amyloid PET assessment that enable
detection of early phases of Ab pathology.References
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